3/17
05:14 pm
imrx
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival [Yahoo! Finance]
Low
Report
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival [Yahoo! Finance]
3/17
04:35 pm
imrx
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Low
Report
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
3/9
08:03 am
imrx
Immuneering (IMRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
Immuneering (IMRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.
3/7
02:59 am
imrx
Medium
Report
3/6
08:25 am
imrx
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/6
07:45 am
imrx
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Medium
Report
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
3/2
04:40 pm
imrx
Immuneering to Present at the Leerink Global Healthcare Conference [Yahoo! Finance]
Low
Report
Immuneering to Present at the Leerink Global Healthcare Conference [Yahoo! Finance]
3/2
04:05 pm
imrx
Immuneering to Present at the Leerink Global Healthcare Conference
Low
Report
Immuneering to Present at the Leerink Global Healthcare Conference
2/28
02:23 am
imrx
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 [Yahoo! Finance]
Low
Report
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 [Yahoo! Finance]
2/18
04:37 pm
imrx
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/18
04:05 pm
imrx
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
1/11
10:32 am
imrx
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
High
Report
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]
1/10
07:02 pm
imrx
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
High
Report
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]
1/8
05:51 pm
imrx
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
Low
Report
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]
1/7
04:00 pm
imrx
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
High
Report
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
12/30
03:52 pm
imrx
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]
Low
Report
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]